Business
Toronto Stock Exchange, Medexus Pharmaceuticals, The View From The C-Suite
Toronto Stock Exchange, Medexus Pharmaceuticals, The View From The C-Suite Cana...
About this update from Medexus Pharmaceuticals Inc.
[{"type":"text","content":"\n \n \n \n Toronto Stock Exchange, Medexus Pharmaceuticals, The View From The C-Suite\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n \n TORONTO\n \n \n ,\n \n \n May 26, 2022\n \n \n /CNW/ -  Ken D'Entremont, Chief Executive Officer, Medexus Pharmaceuticals (Medexus) (TSX: MDP) shares his Company's story in an\n \n \n interview\n \n \n with TMX Group.\n \n \n \n \n \n \n \n \n The View From The C-Suite video interview series highlights the unique perspectives of listed companies on Toronto Stock Exchange and TSX Venture Exchange. Videos provide insight into how company executives think in the current business environment. To see the latest View From The C-Suite visit\n \n https://www.tmxmoney.com/en/csuite.html\n \n .\n \n \n \n \n About Medexus Pharmaceuticals, (TSX: MDP)\n \n \n \n \n Medexus is a leader in innovative rare disease treatment solutions with a strong North American commercial platform and a portfolio of proven best-in-class products. Their current focus is on the therapeutic areas of hematology, auto-immune diseases, and allergy. They continue to build a highly differentiated company with a growing portfolio of innovative and high-value orphan and rare disease products that will underpin their growth for the next decade.\n \n \n \n \n SOURCE Toronto Stock Exchange\n \n \n \n \n \n \n View original content to download multimedia:\n \n http://www.newswire.ca/en/releases/archive/May2022/26/c9994.html\n \n \n \n \n\n","length":3661,"tagName":"div"}]